A Once-Monthly Schizophrenia Shot Just Won FDA Approval

A Once-Monthly Schizophrenia Shot just cleared the FDA, and it could quietly change the daily math of living with schizophrenia. The agency approved Weltruza on October 9, 2026, the first under-the-skin olanzapine injection that lasts a full month, according to drugmaker Teva Pharmaceuticals. It requires no loading doses, no daily pills taken alongside it and no hours of observation after each injection.

That last detail matters more than it sounds. Schizophrenia is a condition where staying on medication is often the hardest part of treatment, and missing doses can spiral into relapse, hospitalization and disrupted lives. Teva's chief medical officer Eric Hughes said the monthly shot is designed to chip away at exactly that problem, telling a company webcast that a simple under-the-skin injection could take adherence out of the daily equation, as reported by Healio. An estimated one and a half million people in the United States are being treated for schizophrenia, and Hughes noted that roughly a fifth of them take daily oral olanzapine, the same medicine this shot delivers in slow release.

What the big trial found

Approval rests on a large phase three trial that enrolled six hundred seventy-five adults between the ages of eighteen and sixty-four. For eight weeks the study ran randomized, double-blind and placebo-controlled, then followed participants through an additional forty-eight weeks to check long-term safety. Every one of the three monthly dose groups showed significant improvement in overall symptoms compared with placebo, and the gains extended beyond symptom scores to illness severity and day-to-day social functioning.

The longer follow-up produced the numbers that will matter most to patients and families. After six months, fifty-six percent of participants had reached a stable state on the monthly shot, and twenty-one percent had achieved full remission. The most common side effects were weight gain, drowsiness, headache, constipation and reactions at the injection site, and the label carries a boxed warning about increased mortality risk in elderly patients with dementia-related psychosis. Discontinuations due to side effects were low and close to placebo levels, which is one reason regulators were comfortable.

Why the older shot was such a hassle

A long-acting olanzapine injection already existed, but it came with strings attached. The older version goes into muscle rather than under the skin and must be given at a certified clinic, followed by hours of monitoring after every single injection because of a rare risk of sudden sedation. For many patients that meant half a day in a waiting room, every month, indefinitely. The new formulation removes the monitoring requirement entirely, which Teva says addresses one of the biggest practical barriers in schizophrenia care.

Clinicians outside the company are cautiously enthusiastic. Christoph Correll, a clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell, told HCPLive that olanzapine has been a trusted foundation of schizophrenia treatment for more than three decades, but that sticking with daily pills remains a major barrier to stability. A monthly under-the-skin option that reaches therapeutic blood levels without booster shots or oral overlap, he said, gives patients, their care partners and their doctors a genuinely new tool. The medicine is expected to reach clinics in the coming weeks in three monthly strengths matched to the usual daily doses. That rollout matters because the people most likely to benefit are often the ones least able to navigate a complicated start. There is no titration schedule to follow, no overlap period juggling pills and shots, and no mandatory waiting-room stakeout afterward. For care partners who currently organize a loved one's entire medication routine, one appointment a month is a radically simpler job.

None of this makes schizophrenia simple. Weight gain and metabolic changes seen with the oral version show up with the shot too, and a monthly clinic visit is its own kind of commitment. But for people whose lives have been organized around remembering a pill every single day, a Once-Monthly Schizophrenia Shot that works in the background is a meaningful shift. Anyone considering a switch should talk it through with their own doctor first, since this article is news, not medical advice. For more on how new treatments are reaching patients, see our coverage of the childhood antibiotics study, new presbyopia eye drops and Army testosterone screening results.